TABLE 2

Individual effects of nine polymorphisms on type 2 diabetes risk with and without adjustment for covariates

Gene variantRisk alleleGenotype (n)Percent case subjects
Percent control subjectsAll case subjects
Incident type 2 diabetes
PrevalentIncidentOR (95% CI)Crude HR (95% CI)Adjusted HR (95% CI)*
ADAMTS9CCC (3,450)61.961.157.41.01.01.0
rs4411878CT (2,159)32.534.737.10.84 (0.74–0.97)0.88 (0.73–1.05)0.87 (0.73–1.04)
TT (321)5.64.25.50.84 (0.62–1.13)0.68 (0.45–1.04)0.68 (0.45–1.04)
CDC123/CTT (3,952)64.467.467.91.01.01.0
CAMK1DTC (1,758)31.528.829.61.04 (0.90–1.20)0.98 (0.82–1.19)0.98 (0.81–1.18)
rs11257622CC (213)4.23.83.51.18 (0.84–1.64)1.07 (0.69–1.67)1.05 (0.68–1.63)
CDKAL1CGG (3,097)47.145.448.71.01.01.0
rs7754840GC (2,692)41.143.041.91.05 (0.93–1.20)1.09 (0.92–1.29)1.10 (0.93–1.31)
CC (633)11.811.69.41.31 (1.07–1.61)1.31 (1.001–1.72)1.38 (1.06–1.80)
CDKN2A/BAAA (1,915)31.335.232.11.01.01.0
rs1412829§AG (2,910)47.750.449.20.97 (0.84–1.12)0.94 (0.78–1.13)0.89 (0.74–1.08)
GG (1,098)21.014.518.70.93 (0.77–1.12)0.72 (0.56–0.94)0.70 (0.54–0.92)
CDKN2A/BTTT (4,131)72.063.166.01.01.01.0
rs10811661TC (1,865)24.734.530.10.95 (0.83–1.09)1.17 (0.99–1.39)1.13 (0.95–1.34)
CC (232)3.22.43.90.70 (0.49–1.02)0.64 (0.37–1.08)0.68 (0.40–1.17)
FTOACC (2,526)38.338.439.81.01.01.0
rs8050136CA (2,944)44.046.346.31.01 (0.88–1.16)1.03 (0.86–1.23)1.00 (0.84–1.20)
AA (927)17.715.314.01.23 (1.02–1.47)1.12 (0.88–1.43)1.06 (0.83–1.36)
HHEXCCC (2,235)36.136.334.81.01.01.0
rs1111875CT (3,097)50.146.148.40.96 (0.84–1.10)0.91 (0.76–1.09)0.93 (0.78–1.12)
TT (1,052)13.717.616.80.89 (0.74–1.07)1.01 (0.80–1.27)1.01 (0.79–1.28)
IGF2BP2TGG (3,101)46.947.749.41.01.01.0
rs4402960GT (2,650)41.841.542.01.04 (0.91–1.18)1.01 (0.85–1.19)1.01 (0.85–1.20)
TT (575)11.310.88.61.35 (1.09–1.66)1.24 (0.95–1.63)1.23 (0.94–1.62)
JAZF1TTT (1,646)31.029.827.11.01.01.0
rs1635852TC (2,927)46.548.649.80.85 (0.73–0.98)0.88 (0.73–1.07)0.85 (0.70–1.04)
CC (1,357)22.521.623.10.85 (0.71–1.02)0.86 (0.68–1.09)0.84 (0.66–1.06)
KCNJ11GAA (2,394)37.739.939.21.01.01.0
rs5219AG (2,925)48.346.647.81.00 (0.88–1.15)0.97 (0.81–1.16)0.97 (0.81–1.16)
GG (807)14.013.513.01.07 (0.88–1.30)1.02 (0.79–1.32)1.02 (0.79–1.32)
NOTCH2TCC (4,670)77.879.078.81.01.01.0
rs1493692CT (1,168)20.719.719.61.04 (0.89–1.22)1.03 (0.84–1.27)1.07 (0.86–1.32)
TT (92)1.41.31.60.86 (0.50–1.49)0.75 (0.35–1.57)0.74 (0.35–1.56)
PPARGCCC (4,888)79.776.977.11.01.01.0
rs1801282CG (1,322)19.121.721.10.95 (0.81–1.10)1.03 (0.84–1.25)0.99 (0.81–1.21)
GG (108)1.21.41.80.70 (0.41–1.20)0.76 (0.38–1.54)0.66 (0.33–1.34)
SLC30A8CCC (3,176)49.854.148.81.01.01.0
rs13266634CT (2,709)43.738.242.40.91 (0.80–1.04)0.82 (0.69–0.97)0.84 (0.70–0.99)
TT (546)6.67.78.80.75 (0.59–0.96)0.80 (0.59–1.09)0.84 (0.62–1.14)
TCF2GAA (1,560)25.924.126.81.01.01.0
rs4430796AG (2,924)48.150.749.61.06 (0.91–1.24)1.11 (0.90–1.36)1.14 (0.92–1.40)
GG (1,417)26.125.223.61.16 (0.97–1.39)1.16 (0.91–1.47)1.16 (0.91–1.48)
TCF7L2TCC (3,292)43.747.552.61.01.01.0
rs7903146CT (2,587)42.442.339.71.23 (1.08–1.41)1.19 (1.01–1.41)1.20 (1.01–1.42)
TT (554)13.910.27.71.82 (1.48–2.24)1.48 (1.12–1.95)1.62 (1.22–2.14)
THADATTT (4,608)79.978.877.31.01.01.0
Rs7578597TC (1,227)19.019.021.10.88 (0.75–1.03)0.91 (0.73–1.12)0.90 (0.72–1.12)
CC (94)1.12.21.61.01 (0.60–1.67)1.32 (0.74–2.34)1.51 (0.85–2.67)
TSPAN8/LGR5CTT (3,018)50.448.351.41.01.01.0
Rs1353362**TC (2,409)40.341.840.61.05 (0.92–1.20)1.10 (0.92–1.31)1.08 (0.90–1.29)
CC (493)9.39.98.01.25 (0.99–1.57)1.29 (0.96–1.73)1.21 (0.90–1.62)
WFS1CCC (2,179)40.740.435.81.01.01.0
Rs1412829††CT (2,801)44.645.747.80.83 (0.73–0.96)0.86 (0.72–1.04)0.87 (0.73–1.05)
TT (949)14.713.916.40.77 (0.63–0.93)0.77 (0.59–1.00)0.76 (0.58–0.99)
  • *

    * HR adjusted for age, sex, and BMI;

  • proxy for rs4607103, r2 = 0.95;

  • proxy for rs12779790, r2 = 0.83;

  • §

    § proxy for rs564398, r2 = 0.97;

  • proxy for rs864745, r2 = 0.97;

  • proxy for rs10923931, r2 = 1.0;

  • **

    ** proxy for rs7961581, r2 = 0.96;

  • ††

    †† proxy for rs10010131, r2 = 1.0.